Scott Gottlieb Quotes
Creative destruction is an increasingly prominent feature of modern medical practice.
Gottlieb, Scott. "The Creative Destruction of Medicine." The Wall Street Journal, 2009.
Regulators, like any other group of people, with the exception of an inventor or innovator and his/her team, are ALWAYS way behind the innovators. However, typically the regulators are not even up on innovations after their creation for several years. They generally are not appointed or hired for their technical skills, and Congress rarely provides enough of a budget to hire enough staff to give them the time to keep up with the field. For a professor in a University, this alone requires about half of his time. No agency can allocate that kind of time. Worse, is the ultimate regulators are the legislators—Congress at the Federal level. They often do not invest enough time to read the regulatory legislation upon which they vote, much less keep up with the fields they regulate.
Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.
